(Total Views: 607)
Posted On: 03/02/2023 11:49:54 AM
Post# of 154857
Re: Evil Rabbit #133186
ER,
Good find on the Clinical Trials update on NASH. For quick reference for anyone who wishes to investigate the update, the link below should show the latest 2 updates side-by-side. Additions are in green and edits/deletions are in red with strikeouts.
https://clinicaltrials.gov/ct2/history/NCT045...udyPageTop
Since safety is at the forefront now with regard to the hold, I looked at SAEs.
For 700 mg Leronlimab, there were two SAEs: eye infection bacterial and invasive ductal breast carcinoma.
For 350 mg Leronlimab, there was one SAE: death based on car accident not believed related to treatment.
From a layman's perspective, that looks like a good record. Nice to see them continuing to take care of business.
Good find on the Clinical Trials update on NASH. For quick reference for anyone who wishes to investigate the update, the link below should show the latest 2 updates side-by-side. Additions are in green and edits/deletions are in red with strikeouts.
https://clinicaltrials.gov/ct2/history/NCT045...udyPageTop
Since safety is at the forefront now with regard to the hold, I looked at SAEs.
For 700 mg Leronlimab, there were two SAEs: eye infection bacterial and invasive ductal breast carcinoma.
For 350 mg Leronlimab, there was one SAE: death based on car accident not believed related to treatment.
From a layman's perspective, that looks like a good record. Nice to see them continuing to take care of business.
(8)
(0)
